MVA85A

MVA85A (modified vaccinia Ankara 85A) is a new-generation vaccine against tuberculosis developed by researchers at Oxford University. This vaccine produces higher levels of long-lasting cellular immunity when used together with the old TB vaccine called BCG. Phase I clinical trials have been completed and phase II clinical trials are currently underway in South Africa with the aim of achieving a product licence by 2010.